JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v10i5.15233ArticleResearch Progress on Improving Chronic Inflammation and Endothelial Function of Coronary Atherosclerotic Heart Disease with Integrated Traditional Chinese and Western Medicinehttps://artdesignp.com/journal/JCNR/10/5/10.26689/jcnr.v10i5.15233HuangZheng,ZengQiao,GuJianhui,LuLiping,ZhouYongxi20261052026-05-31The progression of coronary atherosclerotic heart disease (CAD) is closely associated with the persistent activation of chronic low-grade inflammation and vascular endothelial dysfunction. Although percutaneous coronary intervention (PCI) can effectively improve myocardial ischemia, patients often exhibit elevated inflammatory burden, insufficient endothelial repair, and impaired microcirculatory perfusion postoperatively, thereby contributing to a sustained residual cardiovascular risk. In recent years, integrated traditional Chinese (TCM) and Western medicine therapy have demonstrated advantages in multi-targeted, systematic, and comprehensive regulation to interrupt the vicious cycle of inflammatory responses and endothelial damage. This article reviews the modern pathological mechanisms of chronic inflammation and endothelial dysfunction in coronary atherosclerotic heart disease and explores the underlying pathogenesis from a TCM perspective. Within this framework, this article summarizes the foundational and clinical research progress on anti-inflammatory and endothelial protective effects of TCM through regulating inflammatory signaling pathways, protecting the endothelial glycocalyx, improving blood flow shear stress, and modulating immune metabolism. Finally, this article analyzes the limitations of current research in terms of the quality of evidence, the objectification of syndromes, and the elucidation of the material basis for efficacy of Chinese herbal medicine, and outlines future directions for translational medicine research, with the aim of providing a basis for optimizing integrated TCM and Western medicine prevention and treatment strategies for CHD.

Levine G, Bates E, Blankenship J, et al., 2011, 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 58(24): e44–e122.

Serruys P, 2021, Coronary Syndromes After PCI. Lancet, 398(10294): 1233–1246.

Libby P, 2021, Inflammation in Atherosclerosis. Nature, 592: 524–533.

Toldo S, Abbate A, 2018, The NLRP3 Inflammasome in Acute Myocardial Infarction. Nature Reviews Cardiology, 15(4): 203–214.

Hu D, 2020, Expert Consensus on the Diagnosis and Treatment of Coronary Atherosclerotic Heart Disease with Integrated Traditional Chinese and Western Medicine (2020). Chinese Journal of Internal Medicine, 59(4): 261–270.

Zhang A, 2018, Metabolomics in TCM Syndrome Research. Journal of Ethnopharmacology, 213: 310–319.

Li C, 2021, Herbal Compounds Targeting NLRP3 Inflammasome in Cardiovascular Diseases. Phytomedicine, 92: 153737.

Moore K, Tabas I, 2011, Macrophages in the Pathogenesis of Atherosclerosis. Cell, 145: 341–355.

Duewell P, Kono H, Rayner K, et al., 2010, NLRP3 Inflammasomes Are Required for Atherogenesis and Activated by Cholesterol Crystals. Nature, 464(7293): 1357–1361.

Baker R, Hayden M, Ghosh S, 2011, NF-κB, Inflammation, and Metabolic Disease. Cell Metabolism, 13: 11–22.

Murray P, 2017, Macrophage Polarization. Annual Review of Physiology, 79: 541–566.

Ridker P, 2017, CANTOS Trial. New England Journal of Medicine, 377: 1119–1131.

Deanfield J, 2007, Endothelial Function and Dysfunction. Circulation, 115: 1285–1295.

Förstermann U, Sessa W, 2012, Nitric Oxide Synthases. European Heart Journal, 33: 829–837.

Tarbell J, Cancel L, 2016, The Glycocalyx and Vascular Permeability. Journal of Internal Medicine, 280: 97–113.

Choi B, 2010, Endothelial Dysfunction and Microvascular Obstruction. Journal of the American College of Cardiology, 55: 538–546.

Zhang J, 2019, Mitochondrial Dysfunction in CHD Models with Qi Deficiency. Biomedicine & Pharmacotherapy, 118: 109282.

Hardie D, 2016, AMPK: A Central Regulator of Metabolism. Nature Reviews Molecular Cell Biology, 17: 801–819.

Shaffer F, 2017, HRV and Cardiac Function. Frontiers in Public Health, 5: 258.

Weber C, Noels H, 2011, Cell Adhesion Molecules in Atherosclerosis. Nature Medicine, 17: 1112–1121.

Ruggeri Z, 2002, Platelets in Atherothrombosis. New England Journal of Medicine, 347: 1130–1132.

Moore K, Tabas I, 2011, Macrophages and Foam Cell Formation. Cell, 145: 341–355.

Ouchi N, Parker J, Lugus J, et al., 2011, Adipokines in Inflammation and Metabolic Disease. Nature Reviews Immunology, 11(2): 85–97.

Saxton R, Sabatini D, 2017, mTOR Signaling in Metabolism. Cell, 168: 960–976.

Zhou Z, 2021, Tanshinone IIA Attenuates Atherosclerosis via Inhibiting ROS-Mediated NLRP3 Inflammasome Activation. Phytomedicine, 91: 153693.

Li J, 2020, Baicalin Inhibits NLRP3 Inflammasome Activation. International Immunopharmacology, 81: 106195.

Liu X, 2018, Ligustrazine Suppresses NF-κB Activation. Biomedicine & Pharmacotherapy, 103: 1415–1421.

Fan Y, 2012, Panax Notoginseng Saponins Inhibit Inflammation via NF-κB Modulation. Journal of Ethnopharmacology, 141: 222–230.

Hu X, 2020, Danhong Injection Modulates Macrophage Polarization. Frontiers in Pharmacology, 11: 582234.

Zhang W, 2016, Astragaloside IV Improves Endothelial Dysfunction via PI3K/Akt/eNOS. Atherosclerosis, 247: 88–96.

Yang L, 2016, Ginsenoside Rg1 Protects Endothelial Cells via Nrf2/HO-1. Free Radical Biology and Medicine, 97: 229–240.

Boots A, 2008, Quercetin and Oxidative Stress. Mutation Research, 659: 47–52.

Chen Y, 2019, Salvianolic Acids Protect Endothelium and Reduce Adhesion Molecule Expression. Phytomedicine, 62: 152940.